Gilead's Kite Receives FDA Approval for Yescarta Update
Kite, a Gilead company, announced the FDA approved an update to the Yescarta prescribing information removing the previous Limitations of Use in patients with relapsed or refractory primary central nervous system lymphoma. The updated label reinforces the robust safety data of Yescarta in eligible patients with R/R PCNSL; Yescarta is the only CAR T-cell therapy approved for R/R large B-cell lymphoma to have this Limitations of Use removed.
